Drug Profile
SL 901
Alternative Names: SL-901Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator UCB Pharma Inc
- Developer Stemline Therapeutics; UCB Pharma Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Jun 2023 Stemline Therapeutics completes a phase I trial in Solid tumors (Late stage disease) in United Kingdom (PO)(NCT05382936)
- 19 Mar 2022 Phase-I clinical trials in Solid tumours in United Kingdom (PO) (NCT05382936)
- 04 Jan 2022 Phase-I clinical development is ongoing in Europe (PO) (Menarini group pipeline, January 2022)